DUBLIN, July 13, 2021 / PRNewswire / – The “Contract Development and Manufacturing Organization (CDMO) Global and Chinese Market Report, 2021-2025” report was added to ResearchAndMarkets.com offer.

The total size of the global CDMO market in 2019 is $ 63.3 billion, including US $ 7.03 billion at the clinical stage, $ 44.63 billion in the chemical marketing phase and 11.66 billion US dollars in the biological stage. We estimate that by 2025 the total global CDMO market size will be US $ 119.58 billion, with a compound growth rate of 11.2%.

In 2019, the total size of from China The CDMO market was 44.1 billion yuan, whose CDMO chemical scale was 39.22 billion yuan and the CDMO bio scale has been 4.88 billion yuan. We estimate that by 2025, the total size of from China The CDMO market will be 131 billion yuan, with a compound growth rate of 19.9%, of which the CDMO chemical scale is 107.86 billion yuan, and the CDMO bio scale is 23.15 billion yuan, with compound growth rates of 18. Overall, from China The CDMO industry will always maintain rapid growth, among which bio CDMO will experience faster growth.

In recent years, multinational pharmaceutical companies have focused on their core business selling APIs and compounding plants. We believe that with multinational pharmaceutical companies focusing on R&D and production of new treatment technologies, the current production function of chemical drugs will gradually shift to CDMO companies, and the overall ratio of outsourcing is expected to continue to increase.

Overall, CXO penetration rates in the different stages of R&D and production are quite different. Based on the current penetration rates in various fields of pharmaceutical outsourcing, the penetration rates of pharmacological and toxicological evaluation, API production outsourcing and clinical stage are relatively high, which are respectively of 55%, 35% and 33%, while the penetration rates of preparation development and API development are only 16% and 9%. This is mainly due to the high demands on technological innovation and research capacity of outsourcing companies in the preparation development and API development, and only a small number of CXO companies with innovation capacity independent may be competent.

We expect the bio-CDMO market to experience double-digit annual growth, driven by the expansion of the biomedicine market and improved consignment rate. We also anticipate an acceleration in the growth of the CDMO market through consignment manufacturing of COVID-19 vaccines. Fujifilm HD, JSR and other Japanese companies are making the bio-CDMO business a central part of their growth strategies, and this business could help expand earnings.

Biomedicines and CDMO Markets: The global Biomedicines market was worth around 30 tn in FY 3/20. Compared to conventional small molecule drugs, these technologies work at the genetic and cellular levels and achieve high precision. We expect the market to continue to grow at a double digit rate. Currently, the biomedicine outsourcing rate is around 12%, a fairly low level compared to 30% in the small molecule drug market.

Biomedicines require more sophisticated manufacturing and quality control. Developers of Biomedicine Outsourcing products include many venture capital firms with modest capital accumulation, in addition to large pharmaceutical companies. We expect double-digit growth in the CDMO biologic drug market (bio-CDMO), driven by the expansion of the biologic drug market and the resumption of the rate of outsourcing.

In recent years, international CDMO giants such as Catalent and Lonza have continued to expand cell and gene therapy capabilities through mergers and acquisitions. Lonza first achieved the production of 2000L of adeno-associated virus CMO, with more than 50 viral vector clients and more than 120 nuclear gene therapy projects; Catalent has a production area of ​​over 400,000 square feet and 60 gene therapy projects. In 2020, it strengthened its presence with the acquisition of MaSTherCell.

WuXi PharmaTech is the first to deploy cell gene therapy in China and has accumulated a good research and development pipeline from customers. WuXi PharmaTech developed the cell and gene therapy business in advance many years ago and now has 31 clinical stages of cell and gene therapy CDMO projects; 23 phase I clinical trials; eight phase II / III clinical trials.

Main topics covered:

1. A glance at CDMO

2. Policy overview

3. Driving forces of the Chinese CDMO industry
3.1 The return on investment of innovative drugs is declining
3.2 The R&D commitment of pharmaceutical companies remains high
3.3 The share of emerging peers in R&D pipelines continues to increase
3.4 The rise of national innovative medicines creates additional space
3.5 COVID-19 vaccines and therapeutic drugs

4. Global and Chinese CDMO Market Overview and Forecast
4.1 CDMO – Clearing of M&A transactions
4.2 Global CDMO Market
4.3 Chinese CDMO market

5 Competitive landscape
5.1 Small molecule CDMO
5.2 Macromolecular CDMO

6. Depth insight from foreign and domestic peers

• Lonza
• Catalent
• Samsung organic products
• FUJIFILM Diosynth
• Asymchem
• Wuxi organic products
• Pharmaron inc.
• SynTheAll Pharmaceutical
• Jiuzhou Pharmaceutical
• 3SBio Inc.
• Lianhe chemical technology
• Laviana Pharma
• PharmaResources (Shanghai)
• Shanghai Chem partner
• Facade labs
• Viva Biotech (Shanghai)

For more information on this report, visit https://www.researchandmarkets.com/r/e5ek48

Media contact:

Research and markets
Laura Wood, senior
[email protected]

For EST office hours, call + 1-917-300-0470
For USA / CAN call toll free + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900

US Fax: 646-607-1904
Fax (outside the United States): + 353-1-481-1716

SOURCE Research and Markets

Related links

http://www.researchandmarkets.com